June 22, 2001

Neurochem Honoured With Prestigious "Prix de l'Emergence" From The "Fondation Armand-Frappier"

Neurochem Inc. (TSX : NRM) is pleased to announce it has received The Fondation Armand-Frappier 2001 Award in the "Emergence" category. This award was created to honour Quebec life science and biotechnology companies that are less than 15 years old and have distinguished themselves by virtue of exceptional research and development efforts.

Established in 1993, Neurochem has emerged with dual expertise in the research and development of therapeutics for the central nervous system (CNS) and amyloid-related diseases including Alzheimer's Disease, Hemorrhagic Stroke due to Cerebral Amyloid Angiopathy, Type II Diabetes and Secondary Amyloidosis. To date, the Company has three products advanced into clinical trials, including one ongoing pivotal Phase II/III study; the Company has also eight issued key patents and has 74 active patent applications currently under review.

"Given the quantity and high quality of the biotech research that is taking place in Quebec, we are honoured to be recognized with this award," said Dr. Louis R. Lamontagne, President and CEO, Neurochem Inc. "This is an especially rewarding way to round-out our fiscal year, which ends this month. Throughout the year, we have advanced our dual expertise in CNS and amyloid-related diseases; furthermore, we have maintained our global leadership by being the only Company to be engaged in a pivotal Phase II/III study for an amyloid-related disease."

About Les Prix Fondation Armand-Frappier

The Armand-Frappier Foundation was established in 1978. Its mission is to raise funds to sustain a variety of research programs and purchase highly specialized scientific equipment, and fund specific projects for the Armand-Frappier Institute. These programs aim to achieve excellence internationally and initiate new research opportunities. The awards were established in 1994 to recognize companies which are distinguished by their scientific innovations or by virtue of commercial success or finally by exceptional contributions to research and development.

About Neurochem

Neurochem is a leader in the development of novel, proprietary compounds that inhibit the formation, deposition and toxic effects of amyloid fibrils within the body. Neurochem's research team has been working with international amyloid experts on the development of therapeutic cures to amyloid-related diseases, including Alzheimer's Disease, Secondary Amyloidosis, Diabetes Type II and Hemorrhagic Stroke due to Cerebral Amyloid Angiopathy. Neurochem has advanced three drug candidates to clinical trials : Alzhemed™, for Alzheimer's Disease, Fibrillex™, in a pivotal Phase II/III clinical trial, for Secondary Amyloidosis and Cerebril™, for Hemorrhagic Stroke.

At present, the Company employs over 72 people and is located in Saint-Laurent, Canada (www.neurochem.com).

All of the statements contained in this news release, other than statements of fact which are independently verifiable at the date hereof, are forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the pharmaceutical industry, changes in the regulatory environment in the jurisdictions in which Neurochem does business, stock market volatility, fluctuations in costs, and changes to the competitive environment due to consolidation or otherwise. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements.

For further Information, please contact:
Dr. Lise Hébert
Vice President, Corporate Communications
lhebert@neurochem.com

275 Armand-Frappier
Laval (Quebec)
H7V 4A7
Tel: (450) 680-4500
Fax: (450) 680-4501

Our site is best viewed with IE4+ at a resolution of 1024×768.
All contents copyright © 1998-2007 Neurochem Inc.
Terms, Conditions and Legal Notice.